{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:42:15Z","timestamp":1793652135113,"version":"4.5.1"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jlb.2024.100146","type":"journal-article","created":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T10:29:49Z","timestamp":1707647389000},"page":"100146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Liquid biopsy into the clinics: Current evidence and future perspectives"],"prefix":"10.1016","volume":"4","author":[{"given":"Myrto","family":"Boukovala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8038-7351","authenticated-orcid":false,"given":"Victoria","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2024.100146_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2021.08.002","article-title":"Cancer Biomarkers in the era of precision oncology: addressing the needs of patients and health systems","volume":"84","author":"Normanno","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.jlb.2024.100146_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.jlb.2024.100146_bib3","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/1078-0432.CCR-17-0454","article-title":"Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine","volume":"23","author":"Husain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jlb.2024.100146_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/fon-2020-0074","article-title":"Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA","volume":"16","author":"Zhang","year":"2020","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112652","article-title":"Urine as a source of liquid biopsy for cancer","volume":"13","author":"Oshi","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.jlb.2024.100146_bib6","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib7","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/1878-0261.12574","article-title":"Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions","volume":"13","author":"Villatoro","year":"2019","journal-title":"Mol Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112798","article-title":"Diving into the pleural fluid: liquid biopsy for metastatic malignant pleural effusions","volume":"13","author":"Sorolla","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jlb.2024.100146_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4143\/crt.2019.700","article-title":"Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.jlb.2024.100146_bib10","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","article-title":"Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid","volume":"34","author":"Pentsova","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7741","key":"10.1016\/j.jlb.2024.100146_bib11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3324\/haematol.2019.241208","article-title":"Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jlb.2024.100146_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ma12040654","article-title":"Salivary exosomes as nanocarriers for cancer biomarker delivery","volume":"12","author":"Cheng","year":"2019","journal-title":"Materials"},{"issue":"8","key":"10.1016\/j.jlb.2024.100146_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.adaj.2023.05.006","article-title":"Saliva diagnostics: salivaomics, saliva exosomics, and saliva liquid biopsy","volume":"154","author":"Nonaka","year":"2023","journal-title":"J\u00a0Am Dent Assoc"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid biopsy: general concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol"},{"issue":"403","key":"10.1016\/j.jlb.2024.100146_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1373\/clinchem.2017.277517","article-title":"Incidental detection of maternal neoplasia in noninvasive prenatal testing","volume":"64","author":"Dharajiya","year":"2018","journal-title":"Clin Chem"},{"issue":"6378","key":"10.1016\/j.jlb.2024.100146_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/gutjnl-2012-304149","article-title":"Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer","volume":"63","author":"Church","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jlb.2024.100146_bib22","unstructured":"Epigenomics. Epi proColon\u00ae 2.0 CE. 2019 November 2023]; Available from: https:\/\/www.epiprocolon.com\/wp-content\/uploads\/sites\/3\/2019\/08\/MKT_0049DE_Epi_proColon_20CE_Medical_Professionals_rev3_singles.pdf."},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nmat4997","article-title":"Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma","volume":"16","author":"Xu","year":"2017","journal-title":"Nat Mater"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib24","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/annonc\/mdy119","article-title":"Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification","volume":"29","author":"Liu","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"issue":"7732","key":"10.1016\/j.jlb.2024.100146_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"issue":"47","key":"10.1016\/j.jlb.2024.100146_bib27","doi-asserted-by":"crossref","first-page":"18761","DOI":"10.1073\/pnas.1313995110","article-title":"Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing","volume":"110","author":"Chan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.jlb.2024.100146_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"issue":"7761","key":"10.1016\/j.jlb.2024.100146_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"issue":"466","key":"10.1016\/j.jlb.2024.100146_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jlb.2024.100146_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s43856-022-00088-6","article-title":"Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test","volume":"2","author":"Hinestrosa","year":"2022","journal-title":"Commun Med"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2017.07.004","article-title":"Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets","volume":"32","author":"Best","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12967-023-04417-8","article-title":"Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors","volume":"21","author":"Campolo","year":"2023","journal-title":"J\u00a0Transl Med"},{"issue":"4","key":"10.1016\/j.jlb.2024.100146_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.molonc.2014.12.003","article-title":"Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types","volume":"9","author":"Lebofsky","year":"2015","journal-title":"Mol Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib36","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1158\/1535-7163.MCT-20-1066","article-title":"Genome-wide sequencing of cell-free DNA enables detection of copy-number alterations in patients with cancer where tissue biopsy is not feasible","volume":"20","author":"Jensen","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib37","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jlb.2024.100146_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad040","article-title":"Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis","volume":"7","author":"Mittal","year":"2023","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12916-023-02849-z","article-title":"Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis","volume":"21","author":"Zhong","year":"2023","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib40","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s10238-022-00924-y","article-title":"Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Guo","year":"2023","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.jlb.2024.100146_bib43","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.jlb.2024.100146_bib44","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"504","key":"10.1016\/j.jlb.2024.100146_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"346","key":"10.1016\/j.jlb.2024.100146_bib47","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib48","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib49","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.jlb.2024.100146_bib50","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.jlb.2024.100146_bib51","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-21-0271","article-title":"Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France trial","volume":"27","author":"Taieb","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210230","article-title":"Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Chidharla","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jlb.2024.100146_bib53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/fon-2020-0671","article-title":"ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis","volume":"17","author":"Yekeduz","year":"2021","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032939","article-title":"CtDNA's prognostic value in patients with early-stage colorectal cancer after surgery: a meta-analysis and systematic review","volume":"102","author":"Fan","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13842","article-title":"Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: a meta-analysis","volume":"52","author":"Mi","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41416-022-02017-9","article-title":"The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis","volume":"128","author":"Faulkner","year":"2023","journal-title":"Br J Cancer"},{"issue":"302","key":"10.1016\/j.jlb.2024.100146_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.jlb.2024.100146_bib58","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","article-title":"Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease","volume":"7","author":"Olsson","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"10","key":"10.1016\/j.jlb.2024.100146_bib59","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jlb.2024.100146_bib60","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jlb.2024.100146_bib61","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3389\/fonc.2020.01220","article-title":"Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer","volume":"10","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.jlb.2024.100146_bib62","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jlb.2024.100146_bib63","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib64","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12916-022-02681-x","article-title":"Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","volume":"20","author":"Shen","year":"2022","journal-title":"BMC Med"},{"issue":"7867","key":"10.1016\/j.jlb.2024.100146_bib66","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib67","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jlb.2024.100146_bib68","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"issue":"24","key":"10.1016\/j.jlb.2024.100146_bib69","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jlb.2024.100146_bib71","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2007.13.6523","article-title":"Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse","volume":"26","author":"Pachmann","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-023-06942-y","article-title":"Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer","volume":"201","author":"Ma","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/curroncol30010021","article-title":"Increased circulating epithelial tumor cells (CETC\/CTC) over the course of adjuvant radiotherapy is a predictor of less favorable outcome in patients with early-stage breast cancer","volume":"30","author":"Maurer","year":"2022","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.jlb.2024.100146_bib75","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-17-0255","article-title":"Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant \"geparquattro\" trial","volume":"23","author":"Riethdorf","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib76","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/djy018","article-title":"Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis","volume":"110","author":"Bidard","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib77","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","article-title":"Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sparano","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jlb.2024.100146_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132901","article-title":"Prognostic role of circulating tumor cells during induction chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer","volume":"10","author":"Inhestern","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.jlb.2024.100146_bib79","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib80","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.jlb.2024.100146_bib81","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","article-title":"Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma","volume":"25","author":"Maron","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jlb.2024.100146_bib82","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib83","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.jlb.2024.100146_bib84","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jlb.2024.100146_bib85","unstructured":"FoundationOne\u00aeLiquid CDx. [cited 2023 08 October]; https:\/\/www.foundationmedicine.de\/de\/our-services\/liquid.html]."},{"key":"10.1016\/j.jlb.2024.100146_bib86","unstructured":"Guardant360\u00ae [cited 2023 08 October]; https:\/\/guardanthealth.com\/products\/tests-for-patients-with-advanced-cancer\/]."},{"key":"10.1016\/j.jlb.2024.100146_bib87","unstructured":"Administration, U.S.F.a.D. Guardant360 CDx \u2013 P200010\/S008 [cited 2023 08 October]; https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/guardant360-cdx-p200010s008 ]."},{"key":"10.1016\/j.jlb.2024.100146_bib88","unstructured":"Administration, U.S.F.a.D. FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers. [cited 2023 08 October] https:\/\/www.fda.gov\/drugs\/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers]."},{"issue":"16","key":"10.1016\/j.jlb.2024.100146_bib89","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","article-title":"Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary","volume":"77","author":"Kato","year":"2017","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.jlb.2024.100146_bib90","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","article-title":"Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma","volume":"24","author":"Kato","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib91","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-17-1038","article-title":"Next-generation sequencing of tissue and circulating tumor DNA: the UC San Diego Moores Center for personalized cancer therapy experience with breast malignancies","volume":"18","author":"Shatsky","year":"2019","journal-title":"Mol Cancer Therapeut"},{"issue":"17","key":"10.1016\/j.jlb.2024.100146_bib92","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","article-title":"Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma","volume":"23","author":"Schwaederle","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jlb.2024.100146_bib93","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1535-7163.MCT-18-0965","article-title":"Genomic profiling of blood-derived circulating tumor DNA from patients with colorectal cancer: implications for response and resistance to targeted therapeutics","volume":"18","author":"Choi","year":"2019","journal-title":"Mol Cancer Therapeut"},{"issue":"1","key":"10.1016\/j.jlb.2024.100146_bib94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/1878-0261.12791","article-title":"Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients","volume":"15","author":"Charo","year":"2021","journal-title":"Mol Oncol"},{"issue":"3","key":"10.1016\/j.jlb.2024.100146_bib95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","article-title":"Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers","volume":"148","author":"Okamura","year":"2021","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.jlb.2024.100146_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143600","article-title":"Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening","volume":"13","author":"Adashek","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib97","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ijc.32510","article-title":"Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting","volume":"146","author":"Mardinian","year":"2020","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib98","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1158\/1535-7163.MCT-20-0097","article-title":"Survival implications of the relationship between tissue versus circulating tumor DNA TP53 mutations-A perspective from a real-world precision medicine cohort","volume":"19","author":"Rosenberg","year":"2020","journal-title":"Mol Cancer Therapeut"},{"issue":"7","key":"10.1016\/j.jlb.2024.100146_bib99","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","article-title":"Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jlb.2024.100146_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.988303","article-title":"Identification of microsatellite instability and immune-related prognostic biomarkers in colon adenocarcinoma","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib101","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Therapeut"},{"issue":"23","key":"10.1016\/j.jlb.2024.100146_bib102","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/1078-0432.CCR-19-1372","article-title":"Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade","volume":"25","author":"Georgiadis","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jlb.2024.100146_bib103","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.jlb.2024.100146_bib104","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib105","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.jlb.2024.100146_bib106","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jlb.2024.100146_bib107","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fonc.2020.00466","article-title":"Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy","volume":"10","author":"Cao","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.jlb.2024.100146_bib108","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-11-3148","article-title":"Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib","volume":"18","author":"Punnoose","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jlb.2024.100146_bib109","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jlb.2024.100146_bib110","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1078-0432.CCR-19-3467","article-title":"Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers","volume":"26","author":"Parikh","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib112","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Li","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.jlb.2024.100146_bib113","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"De Roock","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7404","key":"10.1016\/j.jlb.2024.100146_bib114","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"7404","key":"10.1016\/j.jlb.2024.100146_bib115","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jlb.2024.100146_bib116","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.22.00364","article-title":"Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer","volume":"41","author":"Topham","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.jlb.2024.100146_bib117","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jlb.2024.100146_bib118","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jlb.2024.100146_bib119","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.5245","article-title":"Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial","volume":"4","author":"Montagut","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jlb.2024.100146_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13665","article-title":"Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer","volume":"7","author":"Van Emburgh","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jlb.2024.100146_bib121","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jlb.2024.100146_bib122","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","article-title":"Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors","volume":"1","author":"Razavi","year":"2020","journal-title":"Nat Cancer"},{"issue":"40","key":"10.1016\/j.jlb.2024.100146_bib123","doi-asserted-by":"crossref","first-page":"66020","DOI":"10.18632\/oncotarget.11791","article-title":"ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib124","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"7447","key":"10.1016\/j.jlb.2024.100146_bib125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jlb.2024.100146_bib126","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jlb.2024.100146_bib127","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","article-title":"Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer","volume":"4","author":"Scher","year":"2018","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.jlb.2024.100146_bib128","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jlb.2024.100146_bib129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jphotobiol.2013.11.006","article-title":"Fluorescence spectroscopic characterization of salivary metabolites of oral cancer patients","volume":"130","author":"Yuvaraj","year":"2014","journal-title":"J\u00a0Photochem Photobiol, B"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib130","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.21873\/anticanres.11239","article-title":"Expression levels of PIWI-interacting RNA, piR-823, are deregulated in tumor tissue, blood serum and urine of patients with renal cell carcinoma","volume":"36","author":"Iliev","year":"2016","journal-title":"Anticancer Res"},{"issue":"16","key":"10.1016\/j.jlb.2024.100146_bib131","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-19-2896","article-title":"Detection of promoter DNA methylation in urine and plasma aids the detection of non-small cell lung cancer","volume":"26","author":"Liu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2024.100146_bib132","doi-asserted-by":"crossref","first-page":"105","DOI":"10.20517\/2394-5079.2017.15","article-title":"Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma","volume":"3","author":"Hann","year":"2017","journal-title":"Hepatoma Res"},{"issue":"4","key":"10.1016\/j.jlb.2024.100146_bib133","article-title":"Integrative analysis and machine learning based characterization of single circulating tumor cells","volume":"9","author":"Iyer","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"7","key":"10.1016\/j.jlb.2024.100146_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/life11070638","article-title":"Machine learning protocols in early cancer detection based on liquid biopsy: a survey","volume":"11","author":"Liu","year":"2021","journal-title":"Life"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib135","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1053\/j.gastro.2022.06.090","article-title":"An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a multicenter cohort study","volume":"163","author":"Nakamura","year":"2022","journal-title":"Gastroenterology"},{"issue":"7802","key":"10.1016\/j.jlb.2024.100146_bib136","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2024.100146_bib137","article-title":"A\u00a0classifier for improving early lung cancer diagnosis incorporating artificial intelligence and liquid biopsy","volume":"12","author":"Ye","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jlb.2024.100146_bib138","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1039\/D0LC00096E","article-title":"A\u00a0web-based automated machine learning platform to analyze liquid biopsy data","volume":"20","author":"Shen","year":"2020","journal-title":"Lab Chip"},{"issue":"5","key":"10.1016\/j.jlb.2024.100146_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106610","article-title":"DEcancer: machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection","volume":"26","author":"Halner","year":"2023","journal-title":"iScience"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195424000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195424000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T16:22:25Z","timestamp":1757434945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195424000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":139,"alternative-id":["S2950195424000110"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2024.100146","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy into the clinics: Current evidence and future perspectives","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2024.100146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100146"}}